A Phase 2 interventional study of Sirolimus and Sirolimus in Dry Eye, sponsored by Santen Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.
Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Santen Pharmaceutical Co., Ltd..
Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 2, and was the 2nd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. is open now. The open studies under Dry Eye Syndromes, anywhere →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 142 across the 12 interventional studies, 35 across the 1 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Santen Inc., one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation compared to Placebo on the signs and symptoms of dry eye in the CAE Model.
Inclusion Criteria include, but are not limited to:
Exclusion Criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sirolimus
Drug: Sirolimus
Drug: Sirolimus
Drug: Sirolimus
Subconjunctival injection of 440 micrograms sirolimus in each eye.
Also known as: MS-R001, rapamycin
Subconjunctival injection of 220 micrograms sirolimus in each eye.
Also known as: MS-R003, rapamycin
Subconjunctival injection of 880 micrograms sirolimus in each eye.
Also known as: MS-R002, rapamycin
Subconjunctival injection of placebo in each eye.
Mean corneal fluorescein staining (inferior region) after CAE exposure.
Time frame: Day 28
Mean ocular discomfort during CAE exposure.
Time frame: Day 28
Safety across treatment groups.
Time frame: Through 28 days
Additional evaluations of dry eye including fluorescein staining, lissamine green staining, conjunctival redness, tear film break-up time, blink rate, ocular protection index, Schirmer's Test, and corneal sensitivity.
Time frame: Day 28
The record gives a start of Apr 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus